Review Article | Published:

The Oligosaccharides of Glycoproteins: Bioprocess Factors Affecting Oligosaccharide Structure and their Effect on Glycoprotein Properties

Bio/Technology volume 9, pages 13471355 (1991) | Download Citation

Subjects

Abstract

In this review, we organize the recent data concerning the effects of bioprocess factors on the oligosaccharide structure of human therapeutic glycoproteins, with particular emphasis on the influence of the host cell. We also discuss the effect of oligosaccharide structure on glycoprotein properties, including antigenicity, immunogenicity and plasma clearance rate.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , and 1988. Glycobiology. Ann. Rev. Biochem. 57: 785–838.

  2. 2.

    and 1990. Environmental effects on protein glycosylation, Bio/Technology 8: 421–427.

  3. 3.

    , , , and 1991. The oligosaccharides of glycoproteins: factors affecting their synthesis and their influence on glycoprotein properties, p. 199–240. In: Frontiers in Bioprocessing II, S. K. Sikdar, M. Bier, and P. Todd, (Eds.). American Chemical Society, Washington, D.C.

  4. 4.

    and 1985. Assembly of asparagine-linked oligosaccharides. Ann. Rev. Biochem. 54: 631–664.

  5. 5.

    and 1990. Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein engineering. Protein Engineering 3: 433–442.

  6. 6.

    and 1990. β Protein C is not glycosylated at asparagine 329. J. Biol. Chem. 265: 11397–11404.

  7. 7.

    , and 1988. Structure and biosynthesis of plant N-linked glycoproteins. Biochem. of Plants 14: 421–463.

  8. 8.

    , and 1987. Protein glycosylation in yeast. Ann. Rev. Biochem. 56: 915–944.

  9. 9.

    and 1987. Protein glycosylation in yeast. Biochim. Biophys. Acta 906: 81–99.

  10. 10.

    , , , , and 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265: 10373–10382.

  11. 11.

    , , , , , , , , , , and 1990. Use of heterologous and homologous signal sequences for secretion of heterologous proteins from yeast. Methods in Enzymol. 185: 421–440.

  12. 12.

    1990. Isolation, characterization, and properties of Saccharomyces cerevisiae mnn mutants with nonconditional protein glycosylation defects. Methods in Enzymol. 185: 440–469.

  13. 13.

    , , , and 1990. The oligosaccharides of influenza virus hemagglutinin expressed in insect cells by a baculovirus vector. Virology 174: 418–429.

  14. 14.

    , , , , , , , , , , , and 1985. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. 82: 7580–7584.

  15. 15.

    , , , , , , , , , , , and 1985. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313: 806–810.

  16. 16.

    , , , , , and 1990. Physiochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. J. Biochem. 107: 352–359.

  17. 17.

    , , and 1989. High-level expression and purification of a recombinant human erythropoietin produced using a baculovirus vector. Blood 74: 652–657.

  18. 18.

    , , , , and 1988. Human tissue-type plasminogen activator synthesized by using a baculovirus vector in insect cells compared with human plasminogen activator produced in mouse cells. Gene 73: 449–457.

  19. 19.

    , , and 1990. Expression, glycosylation, and intracellular distribution of human β-galactosidase in recombinant baculovirus-infected Spodoptera frugiperda cells. Biochem. Biophys. Res. Comm. 167: 746–753.

  20. 20.

    , and 1983. Production of human beta interferon in insect cells infected with a baculovirus expression vector. Mol. Cell. Biol. 3: 2156–2165.

  21. 21.

    and 1991. Asparagine-linked oligosaccharide processing in Lepidopteran insect cells. Temporal dependence of the nature of the oligosaccharides assembled on asparagine-289 of recombinant human plasminogen produced in baculovirus vector-infected Spodoptera frugiperda (IPLB-SF-21AE) cells. Biochem. 30: 6167–6174.

  22. 22.

    , , , , , , , , , , , and 1985. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 315: 641–647.

  23. 23.

    , , , , , , and 1989. Different conformation of purified human recombinant interleukin 1β from Escherichia coli and Saccharomyces cerevisiae is related to different level of biological activity. Biochem. Biophys. Res. Comm. 162: 357–363.

  24. 24.

    , , , and 1990. Secretion of N-glycosylated human recombinant interleukin-1α in Saccharomyces cerevisiae. Gene 88: 297–301.

  25. 25.

    Biosynthesis of glycoproteins: formation of O-linked oligosaccharides, Chapter 4. In: Biology of Carbohydrates, V. 2, V. Ginsburg and P. W. Robbins (Eds.). John Wiley & Sons, NY.

  26. 26.

    and 1989. O-Glycosylation pathway of mucin-type glycoproteins. BioEssays 10: 117–121.

  27. 27.

    , , , , and 1985. Structures of the major carbohydrates of natural human interleukin-2. Eur. J. Biochem. 153: 255–261.

  28. 28.

    , , , , and 1989. Expression of human interleukin-2 in recombinant baby hamster kidney, Ltk, and Chinese hamster ovary cells. J. Biol. Chem. 264: 17368–17373.

  29. 29.

    , , , and 1990. The role of carbohydrate in recombinant human erythropoietin. Eur. J. Biochem. 188: 405–411.

  30. 30.

    , , and 1989. O-linked oligosaccharides from human serum immunoglobulin A1. Biochem. Soc. Trans. 17: 1034–1035.

  31. 31.

    , , and 1988. Structures of the sugar chains of recombinant human granulocyte-colony-stimulating factor produced by Chinese hamster ovary cells. J. Biochem. 103: 544–546.

  32. 32.

    , , , , , , and 1988. The N-linked and O-linked carbohydrate chains of human, bovine and porcine plasminogen. Eur. J. Biochem. 173: 57–63.

  33. 33.

    , , and 1989. O-mannosylation of recombinant human insulin-like growth factor I (IGF-I) produced in Saccharomyces cerevisiae. FEBS Lett. 248: 111–114.

  34. 34.

    , , , , , , , and 1989. Isolation and characterization of a glycosylated form of human insulin-like growth factor I produced in Saccharomyces cerevisiae. J. Biol. Chem. 264: 11444–11449.

  35. 35.

    , , , , , , , , , , and 1990. Yeast-derived recombinant human insulin-like growth factor I: production, purification, and structural characterization. J. Protein Chemistry 9: 95–104.

  36. 36.

    , and 1990. Structure of O-glycosidically linked oligosaccharides synthesized by the insect cell line Sf9. J. Cell. Biochem. 43: 67–79.

  37. 37.

    , , , , , and 1985. Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression system. Proc. Natl. Acad. Sci. 82: 8404–8408.

  38. 38.

    1984. The carbohydrates of glycoproteins, Chapter 2. In: Biology of Carbohydrates, V. 2, V. Ginsburg and P. W. Robbins (Eds.). John Wiley & Sons, NY.

  39. 39.

    1989. Glycoproteins: what are the sugar chains for? Trends in Biochemical Sciences 14: 272–276.

  40. 40.

    and 1989. Glycosyltransferases. J. Biol. Chem. 264: 17615–17618.

  41. 41.

    , , , , , , , , , , and 1989. Cell-type-specific and site-specific N-glycosylation of type I and type II human tissue plasminogen activator. Biochem. 28: 7644–7662.

  42. 42.

    , , , and 1988. Man, apes, and old world monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J. Biol. Chem. 263: 17755–17762.

  43. 43.

    and 1990. Distribution of Galα(1,3)Galβ(1,4)-GlcNAc residues on secreted mammalian glycoproteins (thyroglobulin, fibrinogen, and immunoglobulin G) as measured by a sensitive solid-phase radioimmunoassay. Biochem. 29: 3959–3965.

  44. 44.

    , , , , , and 1988. Comparatives study of the asparagine-linked sugar chains of natural human interferon-β1 and recombinant human interferon-β1 produced by three different mammalian cells. J. Biol. Chem. 263: 17508–17515.

  45. 45.

    , , and 1989. Carbohydrate structure of recombinant human uterine tissue plasminogen activator expressed in mouse epithelial cells. Eur. J. Biochem. 186: 273–286.

  46. 46.

    , , and 1988. Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectroscopy. Biochem. 27: 8618–8626.

  47. 47.

    , , , , , and 1988. Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J. Biol. Chem. 263: 3657–3663.

  48. 48.

    , , , , , and 1989. Carbohydrate structures of human tissue plasminogen activator expressed in Chinese hamster ovary cells, J. Biol. Chem. 264: 14100–14111.

  49. 49.

    , , , , , , , , , , , , and 1988. Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins. Biochem. 27: 5646–5654.

  50. 50.

    , , , and 1990. Transfer and expression of a murine UDP-Gal: β-D-Galα1,3-galactosyltransferase gene in transfected Chinese hamster ovary cells. J. Biol. Chem. 265: 6225–6234.

  51. 51.

    and 1988. Role of terminal fucose residues in clearance of human glycosylated a-amylase. Am. J. Physiol. 255: G374–G381.

  52. 52.

    and 1983. Regulatory mutations in CHO cells induce expression of the mouse embryonic antigen SSEA-1. Cell 35: 303–309.

  53. 53.

    , and 1989. Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of β-galactoside α2,6-sialyltransferase. J. Biol. Chem. 264: 13848–13855.

  54. 54.

    , , and 1990. Transfection of a human a-(1,3) fucosyltransferase gene into Chinese hamster ovary cells. J. Biol. Chem. 265: 1615–1622.

  55. 55.

    1988. Structures, function and transformational changes of the sugar chains of glycohormones. J. Cell. Biochem. 37: 79–90.

  56. 56.

    , , , , and 1990. Regulation of N-acetylglucosaminyltransferase V activity: kinetic comparisons of parental, rous sarcoma virus-transformed BHK, and L-phytohemagglutinin-resistant BHK cells using synthetic substrates and an inhibitory substrate analog. J. Biol. Chem. 265: 6759–6769.

  57. 57.

    , and 1986. Structural variations of O-linked oligosaccharides present in leukosialin isolated from erythroid, myeloid, and T-lymphoid cell lines. J. Biol. Chem. 261: 12787–12795.

  58. 58.

    1984. Glycosylation mutants of animal cells. Ann. Rev. Genet. 18: 525–552.

  59. 59.

    1987. Biochemical characterization of animal cell glycosylation mutants. Methods in Enzymol. 138: 443–458.

  60. 60.

    1989. Chinese hamster ovary cell mutants with multiple glycosylation defects for production of glycoproteins with minimal carbohydrate heterogeneity. Mol. Cell. Biol. 9: 377–383.

  61. 61.

    , and 1989. Regulation of β-galactoside α2,6-sialyltransferase gene expression by dexamethasone. J. Biol. Chem. 264: 1854–1859.

  62. 62.

    , , , , and 1989. Isolation of a cDNA encoding a murine UDPgalactose:β-D-galactosyl-1,4-N-acetyl-D-glucosaminide α-1,3-galactosyltransferase: expression cloning by gene transfer. Proc. Natl. Acad. Sci. USA. 86: 8227–8231.

  63. 63.

    , , , , and 1987. Structure of the carbohydrate moiety of human interferon-β secreted by a recombinant Chinese hamster ovary cell line. J. Biol. Chem. 262: 14600–14605.

  64. 64.

    , , , , , , , and 1990. O-linked sugar chains of human granulocyte colony-stimulating factor protect it against polymerization and denaturation allowing it to retain its biological activity. J. Biol. Chem. 265: 11432–11435.

  65. 65.

    , and 1985. The role of carbohydrate in erythropoietin action. Endocrinology 116: 2293–2299.

  66. 66.

    , , , and 1990. Role of sugar chains in the in vitro biological activity of human erythropoietin produced in recombinant Chinese hamster ovary cells. J. Biol. Chem. 265: 12127–12130.

  67. 67.

    , , , and 1988. Functional effects of aspargine-linked oligosaccharides on natural and variant human tissue-type plasminogen activator. J. Biol. Chem. 263: 15713–15719.

  68. 68.

    and 1990. Glycosylation at Asn-184 inhibits the conversion of single-chain to two-chain tissue-type plasminogen activator by plasmin, Biochem. 29: 4175–4180.

  69. 69.

    and 1987. Carbohydrates as antigenic determinants of glycoproteins. Biochem. J. 245: 1–11.

  70. 70.

    and 1967. Candida precipitins. J. Immunol. 98: 220–224.

  71. 71.

    , and 1990. IgE-, IgA-, and IgG-antibody responses to carbohydrate and protein antigens of Candida albicans in asthmatic children. Allergy 40: 54–63.

  72. 72.

    and 1984. Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science 226: 1328–1330.

  73. 73.

    1988. Sialic acids as antigenic determinants of complex carbohydrates. Adv. Exp. Med. Biol. 228: 47–72.

  74. 74.

    and 1987. Antibody binding to the β-subunit of deglycosylated chorionic gonadotropin converts the antagonist to an agonist. J. Biol. Chem. 262: 3891–3896.

  75. 75.

    , , and 1988. Conformation of the β-subunit of deglycosylated human chorionic gonadotropin in the interaction at receptor sites. Mol. Cell. Endocrinol. 57: 17–23.

  76. 76.

    , and 1988. Alterations in antigenic structure of gonadotropins following deglycosylation. Bio-science Reports 8: 271–278.

  77. 77.

    , and 1980. Carbohydrate-induced conformational changes of semiliki forest virus glycoproteins determine antigenicity. Virology 102: 286–299.

  78. 78.

    , and 1983. Rabbit anticarbohydrate antibody elicited by the lymphocyte mitogenic glycoprotein from Wistaria floribunda seeds. Mol. Immunol. 20: 727–735.

  79. 79.

    , and 1978. Antibodies against oligosaccharides coupled to proteins: characterization of carbohydrate specificity by radioimmune assay. Arch. Biochem. Biophys. 185: 61–71.

  80. 80.

    , , , , , , and 1990. Recombinant human erythropoietin: 18 months' experience in hemodialysis patients. Am. J. Kidney Dis. 15: 169–175.

  81. 81.

    and 1989. Epoetin (recombinant human erythropoietin): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs 38: 863–899.

  82. 82.

    , , , and 1989. The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am. J. Kidney Dis. 14: 496–506.

  83. 83.

    and 1980. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrin. Metab. 51: 691–697.

  84. 84.

    , , and 1989. Treatment of human muscle creatine kinase with glutaraldehyde preferentially increases the immunogenicity of the native conformation and permits production of high-affinity monoclonal antibodies which recognize two distinct surface epitopes. J. Immunol. Methods 125: 251–259.

  85. 85.

    , and 1970. Immunological activity of cytochrome c. J. Biol. Chem. 245: 947–954.

  86. 86.

    1990. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol. 144: 209–213.

  87. 87.

    , , , , , and 1989. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J. Clin. Oncol. 7: 629–637.

  88. 88.

    , , , , , , , , , and 1985. Phase I evaluation of synthetic mutant of β-interferon. Cancer Res. 45: 5914–5920.

  89. 89.

    , , and 1986. Phase I study of recombinant β ser 17 interferon in the treatment of cancer. Cancer Treat. Rep. 70: 1365–1372.

  90. 90.

    , , and 1987. Assessment of the antigenic response in humans to a recombinant mutant interferon beta. J. Clin. Immunol. 7: 365–375.

  91. 91.

    , and 1974. Hepatic clearance of intact and desialylated erythropoietin. Am. J. of Physiol. 227: 1385–1388.

  92. 92.

    , , and 1989. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 73: 84–89.

  93. 93.

    and 1989. The asialoglycoprotein receptor: properties and modulation by ligand. Prog. Clin. Biol. Res. 300: 169–184.

  94. 94.

    , , , , , , , , , , and 1986. Effects of N-linked carbohydrate on the in vivo properties of human GM-CSF. Cold Spring Harbor Symposia on Quantitative Biology 51: 685–692.

  95. 95.

    and 1988. The structure and function of vertebrate mannose lectin-like proteins. J. Cell. Sci. Suppl. 9: 121–133.

  96. 96.

    1990. The macrophage mannose receptor: current status. Am. J. Respir. Cell Mol. Biol. 2: 317–318.

  97. 97.

    , and 1988. Receptor-mediated endocytosis of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. J. Biol. Chem. 263: 10587–10594.

  98. 98.

    , and 1989. Pharmacokinetics and isolated liver perfusion of carbohydrate modified recombinant tissue-plasminogen activator. Fibrinolysis 3: 79–84.

  99. 99.

    , , , , , , , , , , and 1988. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thomb. Haem. 60: 255–261.

  100. 100.

    1984. Biology of disease: biophysiology of glomerular filtration and proteinuria. Lab. Invest. 51: 7–21.

  101. 101.

    , , , , , , and 1988. Involvement of various organs in the initial plasma clearance of differently glycosylated rat liver secretory proteins. Eur. J. Biochem. 173: 653–659.

  102. 102.

    , , , and 1989. Role of N-glycosylation for the plasma clearance of rat liver secretory glycoproteins. Biochem. Soc. Trans.:17: 21–23.

  103. 103.

    , and 1986. The role of complement and its receptor in the elimination of immune complexes. New Eng. J. Med. 315: 488–495.

  104. 104.

    1989. Human IgG Fc receptors. Clin. Immunol. Immunopath. 53: S63–S71.

  105. 105.

    1989. Immune complex modulation by plasma proteins. With special reference to the complement system and autoimmune diseases. Danish. Med. Bull. 36: 443–463.

  106. 106.

    , , , and 1981. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 289: 496–497.

  107. 107.

    and 1983. Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in an intermittent schedule in cancer patients. J. Natl. Cancer Inst. 70: 1041–1046.

  108. 108.

    , , , , , and 1983. Antibodies to human leucocyte interferons in cancer patients. Lancet, 2: 81–87.

  109. 109.

    , , , , , and 1990. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335: 434–437.

  110. 110.

    , , and 1990. Auto-antibodies to cytokines—friends or foes? Immunol. Today 11: 167–169.

  111. 111.

    , , , , , , , , , , and 1990. Pharmacokinetics in chimpanzees of recombinant human tissue-type plasminogen activator produced mouse C127 and Chinese hamster ovary cells. Chem. Pharm. Bull. 38: 517–522.

  112. 112.

    , , and 1990. Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells. Thrombosis Res. Supplement X: 63–71.

  113. 113.

    , , and 1990. Different receptors mediate the hepatic catabolism of tissue-type plasminogen activator and urokinase. Biochem. J. 267: 647–652.

  114. 114.

    , , , and 1985. Primary structure of two sialylated triantennary glycans from human serotransferrin. FEBS Lett. 183: 65–69.

Download references

Author information

Author notes

    • Charles F. Goochee
    •  & James R. Rasmussen

    Corresponding authors.

Affiliations

  1. Department of Chemical Engineering, Stanford University, Stanford, CA 94305-5025.

    • Charles F. Goochee
    • , Michael J. Gramer
    • , Dana C. Andersen
    •  & Jennifer B. Bahr
  2. Genzyme, 75 Kneeland St., Boston, MA 02111.

    • James R. Rasmussen

Authors

  1. Search for Charles F. Goochee in:

  2. Search for Michael J. Gramer in:

  3. Search for Dana C. Andersen in:

  4. Search for Jennifer B. Bahr in:

  5. Search for James R. Rasmussen in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt1291-1347

Further reading